IDEXX Laboratories, Inc. $IDXX Shares Bought by J. Safra Sarasin Holding AG

Key Points

• J. Safra Sarasin Holding AG increased its holdings in IDEXX Laboratories by 74.2%, acquiring 1,538 additional shares, bringing their total ownership to 3,610 shares worth approximately $1.94 million.
• IDEXX's stock has recently seen multiple ratings upgrades from major analysts, with JPMorgan Chase & Co. raising the target price from $550 to $675, reflecting strong confidence in the company's performance.
• Insiders at IDEXX Laboratories sold a total of 54,057 shares in the last quarter valued at around $34.3 million, with significant sales by both the CEO and an executive vice president.

J. Safra Sarasin Holding AG lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 74.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 3,610 shares of the company's stock after acquiring an additional 1,538 shares during the period. J. Safra Sarasin Holding AG's holdings in IDEXX Laboratories were worth $1,936,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of IDXX. Platinum Investment Management Ltd. purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at $1,877,000. Robeco Institutional Asset Management B.V. grew its stake in IDEXX Laboratories by 39.8% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 207,228 shares of the company's stock valued at $111,145,000 after purchasing an additional 58,991 shares during the last quarter. Heritage Financial Services LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at about $220,000. Madrona Financial Services LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at about $224,000. Finally, Ninety One SA PTY Ltd boosted its position in IDEXX Laboratories by 3.6% in the second quarter. Ninety One SA PTY Ltd now owns 6,222 shares of the company's stock valued at $3,337,000 after buying an additional 214 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research report on Monday, August 4th. Leerink Partners upped their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a report on Friday, August 15th. Finally, Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research note on Monday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $656.50.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the transaction, the executive vice president directly owned 7,132 shares of the company's stock, valued at $4,477,041.68. This trade represents a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares in the company, valued at approximately $52,650,885.78. The trade was a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,057 shares of company stock valued at $34,293,468. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $631.19 on Friday. The company has a market capitalization of $50.50 billion, a P/E ratio of 52.56, a P/E/G ratio of 4.10 and a beta of 1.58. The business's 50 day moving average is $634.52 and its two-hundred day moving average is $534.79. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the firm posted $2.44 EPS. The business's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.